InnoCare Pharma Limited

SEHK:9969 Stok Raporu

Piyasa değeri: HK$13.5b

InnoCare Pharma Yönetim

Yönetim kriter kontrolleri 3/4

InnoCare Pharma CEO'su Jasmine Cui, Aug2016 tarihinde atandı, in görev süresi 8.25 yıldır. in toplam yıllık tazminatı CN¥ 22.63M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.8% maaş ve 79.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 5.73% ine doğrudan sahiptir ve bu hisseler HK$ 775.07M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 9 yıldır.

Anahtar bilgiler

Jasmine Cui

İcra Kurulu Başkanı

CN¥22.6m

Toplam tazminat

CEO maaş yüzdesi20.8%
CEO görev süresi8.3yrs
CEO sahipliği5.7%
Yönetim ortalama görev süresi3.2yrs
Yönetim Kurulu ortalama görev süresi9yrs

Son yönetim güncellemeleri

Recent updates

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Oct 21
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Sep 13
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22
Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Jun 21
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Apr 02
Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Feb 14
Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Oct 06
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

May 11
Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Apr 11
Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Jan 25
Is InnoCare Pharma (HKG:9969) A Risky Investment?

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Sep 05
Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

InnoCare Pharma (HKG:9969) Is Using Debt Safely

Apr 30
InnoCare Pharma (HKG:9969) Is Using Debt Safely

CEO Tazminat Analizi

Jasmine Cui'un ücretlendirmesi InnoCare Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-CN¥471m

Mar 31 2024n/an/a

-CN¥761m

Dec 31 2023CN¥23mCN¥5m

-CN¥631m

Sep 30 2023n/an/a

-CN¥584m

Jun 30 2023n/an/a

-CN¥867m

Mar 31 2023n/an/a

-CN¥781m

Dec 31 2022CN¥24mCN¥4m

-CN¥887m

Sep 30 2022n/an/a

-CN¥987m

Jun 30 2022n/an/a

-CN¥296m

Mar 31 2022n/an/a

-CN¥78m

Dec 31 2021CN¥29mCN¥3m

-CN¥65m

Sep 30 2021n/an/a

CN¥60m

Jun 30 2021n/an/a

-CN¥266m

Mar 31 2021n/an/a

-CN¥329m

Dec 31 2020CN¥120mCN¥1m

-CN¥391m

Sep 30 2020n/an/a

-CN¥2b

Jun 30 2020n/an/a

-CN¥2b

Mar 31 2020n/an/a

-CN¥2b

Dec 31 2019CN¥17mCN¥3m

-CN¥2b

Sep 30 2019n/an/a

-CN¥742m

Jun 30 2019n/an/a

-CN¥592m

Mar 31 2019n/an/a

-CN¥571m

Dec 31 2018CN¥26mCN¥2m

-CN¥550m

Tazminat ve Piyasa: Jasmine 'nin toplam tazminatı ($USD 3.18M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 496.15K ).

Tazminat ve Kazançlar: Jasmine 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jasmine Cui (61 yo)

8.3yrs

Görev süresi

CN¥22,626,000

Tazminat

Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jisong Cui
Co-Founder8.3yrsCN¥22.63m5.73%
HK$ 775.1m
Renbin Zhao
VP of Clinical Development & Medical Research and Executive Directorno dataCN¥4.06m8.21%
HK$ 1.1b
Xin Fu
Chief Financial Officerless than a yearVeri yokVeri yok
Nan Gao
Chief Operating Officer3.3yrsVeri yokVeri yok
Yue Tan
Accounting Supervisorno dataVeri yokVeri yok
Xiangyang Chen
Chief Technology Officer5.1yrsVeri yok0.0071%
HK$ 959.4k
Junsu Wang
General Counsel3.2yrsVeri yokVeri yok
Davy Ouyang
VP & Head of Biology3.2yrsVeri yokVeri yok
Jeff Chen
Chief Commercial Officerless than a yearVeri yokVeri yok
Bei Yuan
Secretary of the Boardno dataVeri yokVeri yok
James Deng
Member of Scientific Advisory Board in Sales & Marketingno dataVeri yokVeri yok

3.2yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim: 9969 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jisong Cui
Co-Founder9yrsCN¥22.63m5.73%
HK$ 775.1m
Renbin Zhao
VP of Clinical Development & Medical Research and Executive Director9yrsCN¥4.06m8.21%
HK$ 1.1b
James Deng
Member of Scientific Advisory Board in Sales & Marketingno dataVeri yokVeri yok
Arnold Levine
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Yigong Shi
Non-Executive Director & President of Scientific Advisory Board9yrsVeri yok0.18%
HK$ 23.8m
Zemin Zhang
Member of Scientific Advisory Board9yrsVeri yokVeri yok
Zhanguo Li
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Ronggang Xie
Non-Executive Director3.7yrsVeri yokVeri yok
Lan Hu
Independent Non-Executive Director4.7yrsVeri yokVeri yok
Dandan Dong
Independent Non-Executive Director1.1yrsVeri yokVeri yok

9.0yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 9969 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9 yıldır).